4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC

NCT05980702 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

192

Enrollment

OTHER

Sponsor class

Conditions

HNSCC
Oral Cancer
PD-1

Interventions

DRUG: Pembrolizumab+Carboplatin+albumin-bound paclitaxel:4 courses
DRUG: Pembrolizumab+Carboplatin+albumin-bound paclitaxel:2 courses

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University